Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2002
Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Moerloose Philippe, Boehlen Françoise
Аннотация
PURPOSE: To describe two new antithrombotic agents (fondaparinux and ximelagatran), their mechanisms of action, the clinical studies available and some implications (regional anesthesia, monitoring and antidote) in anesthesia.
SOURCE: Recently published articles on these two new drugs were reviewed.
PRINCIPAL FINDINGS: These two drugs have several interesting properties. Both are of non animal origin, do not induce thrombocytopenia and do not require laboratory controls. In recent studies fondaparinux has shown a better efficacy than low molecular weight heparin in major orthopedic interventions. Ximelagatran, which can be given orally and is in phase III investigation, could replace vitamin K antagonist in the future.
CONCLUSION: Anesthesiologists should be aware of these two new agents, one (fondaparinux) being now already registered in some countries.
SOURCE: Recently published articles on these two new drugs were reviewed.
PRINCIPAL FINDINGS: These two drugs have several interesting properties. Both are of non animal origin, do not induce thrombocytopenia and do not require laboratory controls. In recent studies fondaparinux has shown a better efficacy than low molecular weight heparin in major orthopedic interventions. Ximelagatran, which can be given orally and is in phase III investigation, could replace vitamin K antagonist in the future.
CONCLUSION: Anesthesiologists should be aware of these two new agents, one (fondaparinux) being now already registered in some countries.